Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide through person-to-person contact, causing a public health emergency of international concern. At present, there is no specific antiviral treatment recommended for SARS-CoV-2 infection. Liu Shen capsule (LS), a traditional Chinese medicine, has been proven to have a wide spectrum of pharmacological properties, such as anti-inflammatory, antiviral and immunomodulatory activities. However, little is known about the antiviral effect of LS against SARS-CoV-2. Herein, the study was designed to investigate the antiviral activity of SARS-CoV-2 and its potential effect in regulating the host's immune response. The inhibitory effect of LS against SARS-CoV-2 replication in Vero E6 cells was evaluated by using the cytopathic effect (CPE) and plaque reduction assay. The number of virions of SARS-CoV-2 was observed under transmission electron microscope after treatment with LS. Proinflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quantitative PCR assays. The results showed that LS could significantly inhibit SARS-CoV-2 replication in Vero E6 cells, and reduce the number of virus particles and it could markedly reduce pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-8, CCL-2/MCP-1 and CXCL-10/IP-10) production at the mRNA levels. Moreover, the expression of the key proteins in the NF-κB/MAPK signaling pathway was detected by western blot and it was found that LS could inhibit the expression of p-NF-κB p65, p-IκBα and p-p38 MAPK, while increasing the expression of IκBα. These findings indicate that LS could inhibit SARS-CoV-2 virus infection via downregulating the expression of inflammatory cytokines induced virus and regulating the activity of NF-κB/MAPK signaling pathway in vitro, making its promising candidate treatment for controlling COVID-19 disease.
['Ma|Qinhai|Q|', 'Pan|Weiqi|W|', 'Li|Runfeng|R|', 'Liu|Bin|B|', 'Li|Chufang|C|', 'Xie|Yuqi|Y|', 'Wang|Zhoulang|Z|', 'Zhao|Jin|J|', 'Jiang|Haiming|H|', 'Huang|Jicheng|J|', 'Shi|Yongxia|Y|', 'Dai|Jun|J|', 'Zheng|Kui|K|', 'Li|Xiaobo|X|', 'Yang|Zifeng|Z|']
D000249:Adenosine Monophosphate D000409:Alanine D000818:Animals D000893:Anti-Inflammatory Agents D000998:Antiviral Agents D000073640:Betacoronavirus D000086382:COVID-19 D049109:Cell Proliferation D002478:Cells, Cultured D002522:Chlorocebus aethiops D045424:Complex Mixtures D018352:Coronavirus Infections D006801:Humans D018836:Inflammation Mediators D016328:NF-kappa B D058873:Pandemics D011024:Pneumonia, Viral D000086402:SARS-CoV-2 D015398:Signal Transduction D014771:Virion
Liu Shen capsule Antiviral Anti-inflammatory SARS-CoV-2